JOURNAL OF PRACTICAL HEPATOLOGY ›› 2018, Vol. 21 ›› Issue (3): 431-434.doi: 10.3969/j.issn.1672-5069.2018.03.028

• Hepatoma • Previous Articles     Next Articles

Application of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in forecasting prognosis of patients with primary liver cancer underwent TACE

Fang Xudong, Fang Xiaoming, Chen Dawei, et al   

  1. Department of General Surgery,117TH Hospital,Hangzhou 310013,Zhejiang Province,China
  • Received:2017-08-05 Online:2018-05-10 Published:2018-05-25

Abstract: Objective To investigate the application of neutrophil/lymphocyte ratio(NLR) and platelet/ lymphocyte ratio (PLR) in forecasting prognosis of patients with primary liver cancer (PLC) underwent transcatheter arterial chemoembolization(TACE). Methods A retrospective analysis of 98 patients with PLC was made, and the patients were recruited in our hospital between August 2012 and August 2014. All of them received TACE,and followed-up for three years. The factors influencing 3-year survival rate was estimated by multivariate Logistic analysis, and the receiver operating characteristic curve(ROC) was calculated to determine the efficacy of NLR and PLR in forecasting the patients’ prognosis. Results The 1,2 and 3 year survival rates in the 98 patients with PLC after TACE treatment were 53.1%,42.9% and 39.8%;the 1,2 and 3 year survival rates in 23 patients with NLR≤1.82 were 73.9%,56.5% and 52.2%,while they were 46.7%,38.7% and 36.0%,respectively,(P<0.05) in 75 patients with NLR>1.82;the 1,2 and 3 year survival rates in 30 patients with PLR≤95.65 were 70.0%,60.0% and 53.3%,while they were 45.6%,35.3% and 33.8%,respectively,(P<0.05) in 68 patients with PLR>95.65; multivariate Logistic analysis showed that tumor number≥2,tumor diameter >50 mm and NLR>1.82 were the independent factors that would influence the patients’ prognosis. Conclusion The NLR should be assessed before TACE in patients with PLC,which is a easy marker to obtain and might be useful in clinical practice.

Key words: Hepatoma, Transcatheter arterial chemoembolization, Neutrophils / lymphocytes ratio, Platelets/ lymphocytes ratio, Prognosis